Cytotoxics and High Potency Manufacturing
- All
- APIs
- Aseptic Processing
- cGMP Manufacture
- Cleaning Validation
- Clinical Trial Materials
- Cytotoxics and High Potency Manufacturing
- Excipients
- Extractables and Leachables
- Facilities
- Fill/Finish
- Lyophilization
- Parenterals
- Process Development
- Process Validation
- Risk Management
- Scale-up/Technology Transfer
- Solid Dosage/Creams/Ointments
-
Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
Ardena Acquires Idifarma from Suanfarma and Sodena
Adds spray drying technology and high potency capabilities.09.02.21
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Lonza Extends Large-Scale MAb Commercial Supply Pact
To provide commercial-scale manufacture of monoclonal antibodies under a long-term agreement at Visp site.07.19.21
-
Breaking News | Cytotoxics and High Potency Manufacturing | Industry News | Solid Dosage/Creams/Ointments
Idifarma Launches Accelerated Pathway for Complex Drugs
‘Simply to Clinic’ leverages expertise in oral standard and highly potent drugs to take projects from pre-formulation to clinical trials.07.14.21
-
APIs | Cytotoxics and High Potency Manufacturing | Drug Development
Leverage the Benefits of Biocatalysis with the Right API CDMO
A powerful tool for organic synthesis, enzymatic chemistry has become an established methodology for manufacturing APIs.
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Cytotoxics and High Potency Manufacturing | Industry News
Novasep, Exelixis Ink ADC Manufacturing Agreement
Covers the cGMP clinical manufacturing of a next-generation ADC drug candidate.07.06.21
-
APIs | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Lonza Expands API Development, Mfg. Facility in China
20M CHF investment will include three 1,000L GMP trains and new development and GMP labs with HPAPI capabilities.06.28.21
-
APIs | Cytotoxics and High Potency Manufacturing | Formulation Development | Process Development
Solubility Enhancement of Hydrophobic Drugs and APIs Using Hot Melt Extrusion
Efficient processing and production technology for solid molecular dispersion, HME can provide sustained, modified and targeted drug delivery.Ameya Deshpande, Formulation Scientist, Avomeen 05.25.21
-
Bio News | Breaking News | cGMP Manufacture | Collaborations & Alliances | Cytotoxics and High Potency Manufacturing | Industry News
Avid Bioservices to Manufacture Zynlonta for ADC Therapeutics
Zynlonta is an antibody drug conjugate approved for cancer treatment.Charles Sternberg, Assistant Editor 05.25.21
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Novasep Expands HPAPI Manufacturing Capacity
Responds to increasing customer demand for manufacturing services for antibody drug conjugates.Tim Wright, Editor, Contract Pharma 05.13.21
-
Bio News | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Facilities | Industry News | Solid Dosage/Creams/Ointments
Enteris BioPharma Completes Expansion of Manufacturing Facility
Also launches CDMO business for the development and manufacture of difficult to formulate drugs and highly potent compounds.Tim Wright, Editor, Contract Pharma 05.11.21
-
APIs | Breaking News | Collaborations & Alliances | Cytotoxics and High Potency Manufacturing | Industry News
FDA Approves ADC Therapeutics' Zynlonta
ADC collaborated with CDMO Sterling Pharma Solutions to develop the cancer drug.Tim Wright, Editor, Contract Pharma 05.07.21
-
Bio News | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Sterling Pharma Solutions Acquires ADC Biotechnology
Will establish a center of excellence for bioconjugation and ADC development and manufacturing services.Tim Wright, Editor, Contract Pharma 04.07.21
-
Cytotoxics and High Potency Manufacturing | Facilities | Solid Dosage/Creams/Ointments
Outsourcing Solid Dosage Manufacturing
A Q&A with Dan Dobry, head of drug product commercial development at Lonza Pharma & Biotech.Online Exclusives Tim Wright, Editor, Contract Pharma 03.12.21
-
APIs | Cytotoxics and High Potency Manufacturing
Challenges & Opportunities Facing Small & Emerging Biopharma Companies
A Q&A with Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza.Tim Wright, Editor, Contract Pharma 03.01.21
-
Breaking News | Cytotoxics and High Potency Manufacturing | Drug Delivery | Facilities | Industry News
Inhalation CDMO Vectura Expands HPAPI Capabilities
New facility will increase containment operations at Chippenham, UK site.Contract Pharma Staff 12.14.20
-
APIs | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Piramal Invests $32M to Expand Michigan Facility
Includes additional capacity in Potent and Non-Potent API development and manufacturing.Contract Pharma Staff 12.08.20
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Catalent Invests $10M in Isolator Capabilities to Expand Micronization
Will allow flexible jet milling ops to be carried out at sites in Malvern, PA and Dartford, U.K. under high containment.Contract Pharma Staff 12.04.20
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Lonza Expands HPAPI Capabilities
Invests more than $15 million to expand and upgrade the Tampa, FL site.Contract Pharma Staff 11.18.20
-
Breaking News | Collaborations & Alliances | Cytotoxics and High Potency Manufacturing | Industry News
Lonza Opens Facility for ADC Payload Manufacturing
Expansion is based on agreement with a major biopharma partner that ensures ADC payload supply continuity and flexibility.Contract Pharma Staff 11.05.20
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
CordenPharma Colorado Completes Highly Potent API Lab Expansion
Capable of handling highly potent compounds with an OEL as low as 1ng/m3.Contract Pharma Staff 10.19.20
